Eli Lilly said a high dose of its gene-editing therapy VERV-102 cut cholesterol by 62% in participants in a phase 1 trial, an early readout aimed at LDL lowering with a potential one-time approach. Lilly acquired the program from Verve Therapeutics as part of its $1 billion buyout.